CN107441481B - A menstrual blood stem cell preparation for treating simple skin injury and its preparation method - Google Patents
A menstrual blood stem cell preparation for treating simple skin injury and its preparation method Download PDFInfo
- Publication number
- CN107441481B CN107441481B CN201710686392.5A CN201710686392A CN107441481B CN 107441481 B CN107441481 B CN 107441481B CN 201710686392 A CN201710686392 A CN 201710686392A CN 107441481 B CN107441481 B CN 107441481B
- Authority
- CN
- China
- Prior art keywords
- menstrual blood
- preparation
- cell
- final concentration
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
Abstract
The invention discloses a menstrual blood stem cell preparation for treating simple skin injury and a preparation method thereof, and solves the problems that the repair of tissues after the simple skin injury is carried out by adopting medicaments in the prior art, the repair is unsatisfactory, and scars are obviously formed. The invention comprises cell disruption solution, rhEGF and KGF added into the cell disruption solution; the final concentration of the rhEGF is 0.05-0.1 mu g/mL; the final concentration of the KGF is 0.1-0.5 mug/mL; the cell disruption solution is as follows: with a concentration of 1X 107～2×109The individual/mL of the hematopoietic stem cells are obtained by disruption, filtration and sterilization. The invention has the advantages of achieving better tissue repair effect and the like.
Description
Technical Field
The invention relates to a menstrual blood stem cell preparation, in particular to a menstrual blood stem cell preparation for treating simple skin injury and a preparation method thereof.
Background
Simple skin damage means that the skin damage is accumulated only in the whole skin layer and the superficial part of the subcutaneous tissue. When the skin is seriously injured, deep tissue necrosis can be caused, and if the skin is improperly treated, ulceration can be caused seriously, and the skin can not heal for a long time. The healing of skin wound refers to the repair process of skin tissue after the skin tissue is cut off or defected due to the action of external force, and comprises the complex combination of regeneration of various tissues, granulation tissue proliferation and scar tissue formation, and the synergistic effect of various processes is shown.
Epidermal and other tissue regeneration occurs within 24 hours of wounding, and basal cells at the wound margins begin to proliferate and migrate beneath the clot towards the center of the wound, forming a monolayer of epithelium covering the surface of the granulation tissue. When these cells meet each other, migration stops and they proliferate and differentiate into squamous epithelium. Healthy granulation tissue is important for epithelial regeneration because it provides nutrients and growth factors necessary for epithelial regeneration. If the granulation tissue fails to fill the wound and scar for a long period of time, epithelial regeneration will be delayed. The current treatment means aiming at the simple skin wound mainly comprise: sterilizing and disinfecting the wound surface, preventing infection by using antibiotics and performing conventional debridement and suturing. However, these treatments are only acute phase preventive measures and do not have a direct effect on post-traumatic repair. Even more, improper treatment can aggravate the injury and leave severe scars.
It has been reported in the literature that the menstrual stem cells are the most potent stem cells in self-replication and directed differentiation, which are derived from the endometrium and excreted in vitro through menstrual blood. Its differentiation potential is similar to that of embryonic stem cell, and it has the characteristics of low immunogenicity, no immunological rejection reaction or weak reaction for xenotransplantation, and can be used for curing several diseases, such as lung injury, cirrhosis, myocardial infarction and diabetes, etc. The stem cells can secrete a plurality of cytokines after in vitro culture, and the main biological activities of the cytokines are strong mitosis promotion, participation in induced differentiation of the stem cells and effective participation in growth, regeneration and reconstruction of histiocytes.
The medicament in the prior art is adopted to repair the tissue after the simple skin injury, and the repair has the problems of unsatisfactory condition and obvious scar formation. The effect of tissue repair by using a culture solution of the hematopoietic stem cells or cytokines alone is not satisfactory.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: the medicine in the prior art is adopted to repair tissues after simple skin injury, the repair has the problems of unsatisfactory condition and obvious scar formation, and the aim is to provide a menstrual blood stem cell preparation for treating simple skin injury with more obvious clinical skin repair effect and a preparation method thereof.
The invention is realized by the following technical scheme:
a menstrual blood stem cell preparation for treating simple skin injury comprises a cell disruption solution, and rhEGF and KGF added into the cell disruption solution; the final concentration of the rhEGF is 0.05-0.1 mu g/mL; the final concentration of the KGF is 0.1-0.5 mug/mL;
the cell disruption solution is as follows: with a concentration of 1X 107～2×109The individual/mL of the menstrual blood stem cell solution is obtained by cell disruption and then filtration sterilization.
According to the invention, the high-purity menstrual blood stem cell disruption solution is combined with the rhEGF and the KGF, so that a better tissue repair effect can be achieved, and the embodiment of the embodiment 1-3 shows that the menstrual blood stem cell disruption solution, the rhEGF and the KGF have a mutual promotion effect, so that the effect is excellent.
Further, the menstrual blood stem cells are disrupted by a sonicator. The stem cells were disrupted and then sterilized by filtration using a 0.22 μm filter.
A method for preparing a preparation of a menstrual blood stem cell for treating simple skin injury comprises:
collecting menstrual blood, separating the menstrual blood to obtain a monocyte layer and an inner membrane tissue, transferring the monocyte layer and the inner membrane tissue into a mesenchymal stem cell serum-free culture medium for cultivation, carrying out cell identification when cells are passaged to 3-4 generations, respectively collecting menstrual blood stem cells and culture supernatant after the menstrual blood stem cells with the purity higher than 95% are obtained, and preparing the menstrual blood stem cells and the culture supernatant into the culture medium with the concentration of 1 × 107～2×109The menstrual blood stem cell solution of each/mL is obtained by crushing the menstrual blood stem cells in the menstrual blood stem cell solution and filtering and sterilizingObtaining cell disruption solution;
and adding rhEGF and KGF into the cell disruption solution, wherein the final concentration of the added rhEGF is 0.05-0.1 mu g/mL, and the final concentration of the KGF is 0.1-0.5 mu g/mL.
Furthermore, during the menstrual blood treatment, an equal volume of lymphocyte separation fluid is added, and after centrifugation for 15-25 min at 2500rpm, the monocyte layer and the inner membrane tissue are taken.
Preferably, the mesenchymal stem cell serum-free culture medium is a mesenchymal stem cell serum-free culture medium developed by CellGenix. During cultivation, a T25 culture bottle is used for primary culture, and after 5-10 hours, the culture is continued by using a supernatant to change bottles.
The primary culture mesenchymal stem cell serum-free culture medium is added with bFGF, hLif and gentamicin; the final concentration of the bFGF after being added is 20-40 ng/mL, the final concentration of the hLif after being added is 20-40 ng/mL, and the final concentration of the gentamicin after being added is 300-600 IU/mL.
If the primary culture is pollution-free, only bFGF and hLif are added into the mesenchymal stem cell serum-free culture medium for subculture; if contamination is suspected in primary culture, adding bFGF, hLif and gentamicin into the mesenchymal stem cell serum-free culture medium for subculture; the final concentration of the bFGF after being added is 20-40 ng/mL, the final concentration of the hLif after being added is 20-40 ng/mL, and the final concentration of the gentamicin after being added is 300-600 IU/mL.
Through the optimization of the components and the proportion, the skin repairing effect can be greatly improved, and the effect is very obvious.
Preferably, the filtration sterilization is performed by using a 0.22 μm filter.
Compared with the prior art, the invention has the following advantages and beneficial effects:
1. the invention can effectively achieve the effect of mutual promotion and better tissue repair effect by preparing the menstrual blood stem cell crushing liquid and mutually matching the rhEGF and the KGF.
2. The invention has no problems of immunological rejection, ethics and the like, has strong cell regeneration and repair effects and very obvious effect.
Drawings
The accompanying drawings, which are included to provide a further understanding of the embodiments of the invention and are incorporated in and constitute a part of this application, illustrate embodiment(s) of the invention and together with the description serve to explain the principles of the invention. In the drawings:
FIG. 1 is a microscopic image of the present invention showing the purity of over 95% of menstrual blood stem cells.
FIG. 2 is a section view of the whole skin layer after the treatment of the finished product of example 1, taken at 40-fold magnification.
FIG. 3 is a section view of the whole skin layer after the treatment of the product of example 2, taken at 40-fold magnification.
FIG. 4 is a section view of the staining results of the whole skin layer at 40X after the treatment of the finished product of example 3.
FIG. 5 is a section view of the whole skin layer after the treatment of the product of example 4, taken at 40-fold magnification.
FIG. 6 is a section view of the staining results of the whole skin layer at 40X after the treatment of the finished product of example 5.
FIG. 7 is a section view of the staining results of the whole skin layer at 40X after the treatment of the finished product of example 6.
FIG. 8 is a section view of the staining results of the whole skin layer at 40X after the treatment of the finished product of example 7.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail below with reference to examples, and the exemplary embodiments and descriptions thereof are only used for explaining the present invention and are not used as limitations of the present invention.
Example 1
A menstrual blood stem cell preparation for treating simple skin injury comprises a cell disruption solution, and rhEGF and KGF added into the cell disruption solution.
The preparation method of the cell disruption solution comprises the following steps:
taking 10mL of menstrual blood, adding 10mL of human lymphocyte separation liquid, centrifuging for 15-25 min at 2500rpm, taking a monocyte layer and an inner membrane tissue, adding 5 mL of mesenchymal stem cell serum-free culture medium developed by CellGenix, and transferring into a T25 culture bottle for primary culture. The final concentration of 30ng/mL bFGF, the final concentration of 30ng/mL hLif and the final concentration of 400IU/mL gentamicin are added into the serum-free culture medium of the mesenchymal stem cells. The added bFGF, hLif and gentamicin all accord with GMP standard.
After 8 hours of culture, liquid is changed, namely supernatant in a T25 culture bottle is transferred to a bottle for continuous culture, if primary cells are not polluted, no antibiotic gentamicin is added after passage, and after the cells are passed for 3-4 generations, the menstrual blood stem cells with the purity higher than 95% are obtained, and as shown in figure 1, 10 are collected10The menstrual blood stem cells of (4) were resuspended in 10mL of the culture supernatant to a concentration of 1X 109The cells were disrupted by ultrasonication using a 0.22 μm filter after disrupting the cells in the solution of individual/mL cells.
The GMP-standard rhEGF and KGF were added to the re-cell disruption solution at a final concentration of 0.08. mu.g/mL for the added rhEGF and 0.4. mu.g/mL for the added KGF.
Example 2
This example differs from example 1 in that only the cell disruption solution was used, and rhEGF and KGF were not added to the cell disruption solution.
Example 3
This example is a control of example 1, the formulation in this example consisting only of rhEGF at a final concentration of 0.08. mu.g/mL, and KGF at a final concentration of 0.4. mu.g/mL.
Example 4
This example is a control example of the present invention, the formulation of which consists of physiological saline only.
Example 5
This example is a control example of the present invention, and the formulation in this example consists of rhEGF only at a concentration of 0.2. mu.g/mL.
Example 6
This example is a comparative example of example 1, and the only difference between this example and example 1 is that the concentrations of rhEGF and KGF added to the obtained cell disruption solution are different, and are specifically set as follows:
after rhEGF and KGF were added to the cell disruption solution, the final concentration of rhEGF was 0.16. mu.g/mL and the final concentration of KGF was 0.8. mu.g/mL.
Example 7
This example is a comparative example of example 1, and the only difference between this example and example 1 is that the concentrations of rhEGF and KGF added to the obtained cell disruption solution are different, and are specifically set as follows:
after rhEGF and KGF were added to the cell disruption solution, the final concentration of rhEGF was 0.04. mu.g/mL and the final concentration of KGF was 0.2. mu.g/mL.
The rabbit was tested using the finished products of examples 1-7 as described above in the following manner:
establishing a rabbit model
A surgical injury making mode is adopted, New Zealand rabbits are selected, 10% chloral hydrate is used for anesthesia, two symmetrical areas which are 2cm beside the two sides of the spine and close to forelimbs are selected, and a circular area wound surface with the diameter of 1cm is established. One rabbit selected 6 areas on the back, which injured the dermis.
Second, therapeutic methods
Treatment times were 5 and 10 days, with triplicates per group. The medicine is treated twice a day, 50 microlitre of the medicine is taken each time, and wound infection and repair conditions, rabbit diet action and other reactions are observed in the treatment process.
Third, detection of therapeutic effect
After the treatment period, the rabbits were sacrificed and the skin was taken over all the layers and sent to pathological sections, and each specimen was subjected to double staining, i.e., H & E staining and Masson staining. The detection results are as follows:
1. the normal saline group and the rhEGF group have slight purulent secretion, no obvious infection is seen in the experimental group, and the whole course of treatment is normal in the rabbit diet action.
2. And (3) sorting a repair condition table according to results of H & E dyeing and Masson dyeing, wherein the repair condition is shown in Table 1, the more + in the Table 1 represents the repair degree, the better the repair effect is, and the more + represents that no repair is available.
TABLE 1
| Epidermis | Dermis collagen new layer | Accessory structure | |
| Example 1 | ++++ | +++ | ++ |
| Example 2 | +++ | ++ | - |
| Example 3 | - | + | + |
| Example 4 (physiological saline) | - | - | - |
| Example 5(rhEGF) | - | + | - |
| Example 6 | ++ | ++ | + |
| Example 7 | + | + | + |
3. Providing section images of the staining results of skin wounds at 40 times after 5 days of treatment with the blood stem cell preparations of examples 1 to 7; it can be seen from this picture that:
in fig. 2 there is a complete and continuous skin layer. The collagen structure of the dermis is well defined and the dermal accessory structures begin to regenerate. The crust separated from the epidermal layer. Indicating that inflammatory cell infiltration process which is already healed by the wound surface enters a collagen remodeling stage.
In fig. 3, there is a complete and continuous epidermis layer, but the epidermis is of varying depth, indicating that the wound is in the initial stage of healing. The dermis layer also shows a newly formed collagen layer with irregular arrangement and collagen fibers with regular arrangement. The dermis layer has no accessory structure.
No epidermis layer is visible in fig. 4. The dermis collagen shows two layers, neogenesis and inherent, suggesting the production of neogenesis collagen, and a small amount of dermis accessory structure is seen.
In fig. 5 there is no skin layer. Collagen defect in dermis layer. The inflammatory exudate is much and covers the surface of the dermis directly.
In fig. 6 there is no skin layer. The collagen repair of the dermis is not complete. Inflammatory cell infection is frequent, and the dermis is adhered to the crust.
In FIG. 7, the epidermis is tightly connected to the crust and peeled away during peeling. The dermis is divided into old and new layers, and a small number of accessory structures grow out.
FIG. 8 shows a small amount of discontinuous epidermis with an incomplete structure of only 1-2 layers of cells. The dermis collagen shows two layers, neogenesis and inherent, suggesting the production of neogenesis collagen, and a small amount of dermis accessory structure is seen.
The data in table 1 and the slicing results in fig. 1 to 8 show that:
the results of examples 1 to 3 demonstrate that: according to the invention, the rhEGF and KGF which are in GMP standard are added into the cell disruption solution, so that the cell disruption solution and the added cell factor have a mutual promotion effect; the comparison of the data of the invention with those of examples 6 and 7 demonstrates that: only by adding the growth factor with the concentration of the invention into the culture medium and adding the cell factor with the concentration range of the invention into the cell disruption solution can the mutual promotion effect between the cell disruption solution and the cell factor be effectively achieved; the comparison of the test results of examples 1 to 7 shows that: the preparation obtained under the concentration of the invention has the best repairing effect, which is superior to the control group without adding cell factors and the control group outside the concentration range value.
The comparison of the data of the treatment effect of 10 days and the treatment effect of 5 days in the present invention shows that the comparison results of the treatments of examples 1 to 7 are similar, and only the treatment effect of 10 days is more significant than that of 5 days.
The above-mentioned embodiments are intended to illustrate the objects, technical solutions and advantages of the present invention in further detail, and it should be understood that the above-mentioned embodiments are merely exemplary embodiments of the present invention, and are not intended to limit the scope of the present invention, and any modifications, equivalent substitutions, improvements and the like made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (10)
1. A menstrual blood stem cell preparation for treating simple skin injury is characterized in that,
comprises a cell disruption solution and rhEGF and KGF which are added into the cell disruption solution; the final concentration of the rhEGF is 0.08 mu g/mL; the final concentration of KGF is 0.4 mug/mL;
the cell disruption solution is as follows: with a concentration of 1X 107~2×109The individual/mL of the menstrual blood stem cell solution is obtained by cell disruption and then filtration sterilization.
2. The preparation of claim 1, wherein the hematopoietic stem cells are disrupted by ultrasonication.
3. The preparation of hematopoietic stem cells for treating simple skin injury according to claim 1, wherein the hematopoietic stem cells are sterilized by filtration using a 0.22 μm filter after disruption.
4. A method for preparing a menstrual blood stem cell preparation for treating simple skin injury, which is characterized by comprising the following steps:
collecting menstrual blood, separating the menstrual blood to obtain a mononuclear cell layer and an inner membrane tissue, transferring the mononuclear cell layer and the inner membrane tissue into a mesenchymal stem cell serum-free culture medium for cultivation, carrying out cell identification when cells are passaged to 3-4 generations, respectively collecting menstrual blood stem cells and culture supernatant after the menstrual blood stem cells with the purity higher than 95% are obtained, and preparing the menstrual blood stem cells and the culture supernatant into the culture medium with the concentration of 1 × 107~2×109Crushing the menstrual blood stem cells in the menstrual blood stem cell solution per mL of menstrual blood stem cell solution, and filtering and sterilizing to obtain a cell crushing solution;
and adding rhEGF and KGF into the cell disruption solution, wherein the final concentration of the added rhEGF is 0.08 mu g/mL, and the final concentration of the KGF is 0.4 mu g/mL.
5. The method according to claim 4, wherein an equal volume of lymphocyte separation medium is added during the menstrual blood treatment, and after centrifugation at 2500rpm for 15-25 min, mononuclear cell layers and endothelial tissues are taken.
6. The method for preparing a menstrual blood stem cell preparation for treating pure skin injury according to claim 4, wherein the mesenchymal stem cell serum-free medium is a mesenchymal stem cell serum-free medium developed by CellGenix.
7. The method for preparing a preparation of menstrual blood stem cells for treating simple skin lesions according to claim 6, wherein the culturing is performed by primary culturing in a T25 culture flask, and after 5-10 hours, the culturing is continued by using supernatant spinner flasks.
8. The method for preparing a preparation of menstrual stem cells for treating simple skin injury according to claim 7, wherein bFGF, hLif and gentamicin are added into the primary cultured mesenchymal stem cell serum-free culture medium; the final concentration of the bFGF after being added is 20-40 ng/mL, the final concentration of the hLif after being added is 20-40 ng/mL, and the final concentration of the gentamicin after being added is 300-600 IU/mL.
9. The method for preparing a preparation of menstrual blood stem cells for treating simple skin injury according to claim 8, wherein if there is no contamination in primary culture, the mesenchymal stem cells cultured by subculture are supplemented with bFGF and hLif only; if contamination is suspected in primary culture, adding bFGF, hLif and gentamicin into the mesenchymal stem cell serum-free culture medium for subculture; the final concentration of the bFGF after being added is 20-40 ng/mL, the final concentration of the hLif after being added is 20-40 ng/mL, and the final concentration of the gentamicin after being added is 300-600 IU/mL.
10. The method for preparing a preparation of hematopoietic stem cells for treating simple skin lesions according to claim 4, wherein the filtration sterilization is performed using a 0.22 μm filter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710686392.5A CN107441481B (en) | 2017-08-11 | 2017-08-11 | A menstrual blood stem cell preparation for treating simple skin injury and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710686392.5A CN107441481B (en) | 2017-08-11 | 2017-08-11 | A menstrual blood stem cell preparation for treating simple skin injury and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107441481A CN107441481A (en) | 2017-12-08 |
| CN107441481B true CN107441481B (en) | 2020-12-08 |
Family
ID=60492053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710686392.5A Active CN107441481B (en) | 2017-08-11 | 2017-08-11 | A menstrual blood stem cell preparation for treating simple skin injury and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107441481B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112391338A (en) * | 2020-11-25 | 2021-02-23 | 广东圆康再生医学科技开发有限公司 | Endometrial stem cell extraction |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103305461A (en) * | 2013-07-03 | 2013-09-18 | 顺昊细胞生物技术（天津）有限公司 | Method for preparing mesenchymal stem cells from menstruation product |
| CN104903439A (en) * | 2013-01-09 | 2015-09-09 | 国际干细胞公司 | Small molecules that promote skin regeneration |
| CN106497975A (en) * | 2016-10-21 | 2017-03-15 | 浙江生创精准医疗科技有限公司 | The preparation method of genetic recombination stem cell medicine and its application in skin injury reparation, scar suppress |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170143764A1 (en) * | 2014-06-17 | 2017-05-25 | Cells For Cells S.A. | Menstrual blood-derived stem cells for the treatment of human pancreatic carcinoma |
-
2017
- 2017-08-11 CN CN201710686392.5A patent/CN107441481B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104903439A (en) * | 2013-01-09 | 2015-09-09 | 国际干细胞公司 | Small molecules that promote skin regeneration |
| CN103305461A (en) * | 2013-07-03 | 2013-09-18 | 顺昊细胞生物技术（天津）有限公司 | Method for preparing mesenchymal stem cells from menstruation product |
| CN106497975A (en) * | 2016-10-21 | 2017-03-15 | 浙江生创精准医疗科技有限公司 | The preparation method of genetic recombination stem cell medicine and its application in skin injury reparation, scar suppress |
Non-Patent Citations (3)
| Title |
|---|
| Skin regeneration scaffolds: a multimodal bottom-up approach.;Yildirimer L等;《Trends Biotechnol.》;20121231;第30卷(第12期);第638-648页 * |
| 月经血子宫内膜干细胞在子宫内膜损伤修复中的作用研究;张延玲;《中国优秀博士论文全文数据库》;20170301;第1-100页 * |
| 表皮细胞生长因子复合骨髓间充质干细胞促进大鼠β射线皮肤损伤创面愈合的实验研究;张毓姣;《中国优秀硕士学位论文全文数据库》;20130501;第1-60页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107441481A (en) | 2017-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230405180A1 (en) | Mesenchymal stem cell-hydrogel-biodegradable or mesenchymal stem cell-hydrogel-undegradable support composition for skin regeneration or wound healing | |
| WO2019088656A1 (en) | Filler composition containing stabilized exosomes | |
| Lou et al. | Extracellular vesicle-based therapeutics for the regeneration of chronic wounds: current knowledge and future perspectives | |
| EP1999250B1 (en) | Method of cultivation of human mesenchymal stem cells, particularly for the treatment of non-healing fractures, and bioreactor for carrying out this cultivation method | |
| CN112111451B (en) | Method for increasing yield of stem cell cytokines | |
| RU2574017C1 (en) | Medication for treating burns and wounds based on cytokines and growth factors, secreted by mesenchymal human cells, method for thereof obtaining and method for treating burns and wounds | |
| Wang et al. | Human acellular amniotic matrix with previously seeded umbilical cord mesenchymal stem cells restores endometrial function in a rat model of injury | |
| CN110938587A (en) | Preparation method and application of epidermal stem cell suspension | |
| CN107126556A (en) | A kind of stem cell extract and preparation method thereof and the application in skin wound preparation for repairing is prepared | |
| CN107441481B (en) | A menstrual blood stem cell preparation for treating simple skin injury and its preparation method | |
| CN107779430A (en) | The collection method of umbilical cord mesenchymal stem cells supernatant | |
| CN108066750A (en) | Stem cell and its secretion are used to treat the new application of skin burn | |
| EP3954760A1 (en) | Clinical-grade autologous bronchial basal cell, transfusion formulation, and preparation process | |
| CN111904980B (en) | Mesenchymal stem cells and use in the treatment of acute lung injury, acute respiratory distress syndrome or pulmonary fibrosis | |
| CN112409456A (en) | Application of stem cell cytokine in preparation of cosmetics or medicines | |
| CN105154388B (en) | method for separating and culturing skin keratinocytes | |
| TW201432048A (en) | Composition containing growth factors and method of preparing thereof | |
| RU2620167C1 (en) | Method for obtaining preparation for stimulation of regeneration based on products of secretion of human multipotent mesenchymal stromal cells | |
| CN115820548A (en) | Preparation method and application of apoptotic vesicles derived from animal tissues | |
| RU2148970C1 (en) | Method for repairing skin cover | |
| CN110680949B (en) | Preparation method and application of wound dressing based on breast milk | |
| CN113827618A (en) | Application of stem cell conditioned medium in preparation of medicine for treating inflammatory skin | |
| EP3517606A1 (en) | Method for preparing a supplement from mesenchymal cell cultures of wharton's jelly and uses of same | |
| CN108057131A (en) | A kind of novel agent box containing stem cell | |
| CN112707962A (en) | Carbohydrate-containing protective agent and preservation method of mesenchymal stem cell factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |